Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Mar;65(3):571–576. doi: 10.1172/JCI109701

Metabolic Consequences of Oral Administration of 24,25-Dihydroxycholecalciferol to Uremic Dogs

Janet M Canterbury 1,2, George Gavellas 1,2, Jacques J Bourgoignie 1,2, Eric Reiss 1,2
PMCID: PMC371397  PMID: 7354130

Abstract

24,25-dihydroxycholecalciferol [24,25-(OH)2D3], once considered a relatively inert metabolite of vitamin D3, has been recently recognized as a metabolically active product in some species. In previous studies, we have shown that infusion of 24,25(OH)2D3 into the thyroid artery of normal dogs results in prompt and complete suppression of parathyroid hormone (PTH) secretion. In this study, we have examined the metabolic consequences of oral administration of this metabolite in dogs with experimentally induced renal hyperparathyroidism. Dogs with comparable degrees of renal insufficiency (glomerular filtration rate, 10-15 ml/min) were treated for 3 wk with daily doses of either 2 μg of 24,25(OH)2D3 or 50% ethanol, the vehicle in which the metabolite was suspended. After a 6-wk recovery period, treatments were reversed: dogs who had previously served as controls received the metabolite while dogs previously treated with metabolite received the vehicle. Administration of 24,25(OH)2D3 resulted in a 40-60% decrease of immunoreactive PTH. This was associated with a small (0.1-0.2 mg/dl) but unequivocal decrease of serum ionized calcium. Calcium balance, which was slightly negative under control conditions, became slightly but definitively positive on treatment with 24,25(OH)2D3. All other parameters measured, including total serum calcium, magnesium, phosphorus, creatinine, electrolytes, phosphorus excretion, and phosphorus balance, remained unchanged. The data support the hypothesis that 24,25(OH)2D3 not only decreases PTH secretion but also functions as an anabolic hormone in bone under the conditions of this experiment.

Full text

PDF
571

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brickman A. S., Coburn J. W., Norman A. W. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med. 1972 Nov 2;287(18):891–895. doi: 10.1056/NEJM197211022871801. [DOI] [PubMed] [Google Scholar]
  2. Canterbury J. M., Bricker L. A., Levey G. S., Kozlovskis P. L., Ruiz E., Zull J. E., Reiss E. Metabolism of bovine parathyroid hormone. Immunological and biological characteristics of fragments generated by liver perfusion. J Clin Invest. 1975 Jun;55(6):1245–1253. doi: 10.1172/JCI108043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Canterbury J. M., Lerman S., Claflin A. J., Henry H., Norman A., Reiss E. Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest. 1978 May;61(5):1375–1383. doi: 10.1172/JCI109055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Canterbury J. M., Levey G. S., Reiss E. Activation of renal cortical adenylate cyclase by circulating immunoreactive parathyroid hormone fragments. J Clin Invest. 1973 Feb;52(2):524–527. doi: 10.1172/JCI107211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Canterbury J. M., Reiss E. Multiple immunoreactive molecular forms of parathyroid hormone in human serum. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1393–1398. doi: 10.3181/00379727-140-36681. [DOI] [PubMed] [Google Scholar]
  6. Care A. D., Bates R. F., Pickard D. W., Peacock M., Tomilnson S., O'Riordan J. L., Mawer E. B., Taylor C. M., DeLuca H. F., Norman A. W. The effects of vitamin D metabolites and their analogues on the secretion of parathyroid hormone. Calcif Tissue Res. 1976 Aug;21 (Suppl):142–146. [PubMed] [Google Scholar]
  7. DeLuca H. F., Schnoes H. K. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem. 1976;45:631–666. doi: 10.1146/annurev.bi.45.070176.003215. [DOI] [PubMed] [Google Scholar]
  8. Figueroa W. G., Jordan T., Bassett S. H. Use of barium sulfate as an unabsorbable fecal marker. Am J Clin Nutr. 1968 Nov;21(11):1239–1245. doi: 10.1093/ajcn/21.11.1239. [DOI] [PubMed] [Google Scholar]
  9. Freitag J., Martin K. J., Hruska K. A., Anderson C., Conrades M., Ladenson J., Klahr S., Slatopolsky E. Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med. 1978 Jan 5;298(1):29–32. doi: 10.1056/NEJM197801052980107. [DOI] [PubMed] [Google Scholar]
  10. Haussler M. R., McCain T. A. Basic and clinical concepts related to vitamin D metabolism and action (first of two parts). N Engl J Med. 1977 Nov 3;297(18):974–983. doi: 10.1056/NEJM197711032971804. [DOI] [PubMed] [Google Scholar]
  11. Rutherford W. E., Bordier P., Marie P., Hruska K., Harter H., Greenwalt A., Blondin J., Haddad J., Bricker N., Slatopolsky E. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest. 1977 Aug;60(2):332–341. doi: 10.1172/JCI108781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schultze R. G., Shapiro H. S., Bricker N. S. Studies on the control of sodium excretion in experimental uremia. J Clin Invest. 1969 May;48(5):869–877. doi: 10.1172/JCI106045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Silverman R., Yalow R. S. Heterogeneity of parathyroid hormone. Clinical and physiologic implications. J Clin Invest. 1973 Aug;52(8):1958–1971. doi: 10.1172/JCI107380. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES